Women’s health has been framed as niche and limited to reproductive care, but the data tells a different story. Drawing on AOA Dx’s analysis of 25 years of exits, this talk reveals more than $100B in realized value and 27 unicorn exits. By reframing how the sector is categorized, we uncover a mature, scalable market and what it signals for the next wave of innovation and investment in women’s health.

The global landscape of women’s health continues to be marked by significant unmet needs, with progress often appearing slow and fragmented. This presentation examines the innovation cycle within the MedTech sector and its historical impact on women’s health. It then explores the evolving landscape, highlighting key strategies for securing funding, navigating reimbursement pathways, and successfully launching transformative medical devices in today’s healthcare environment.

Hormones constantly change across the menstrual cycle, making a single blood test non-diagnostic. To truly understand how hormonal changes affect women's health, a better diagnostic platform must be created. Proov invented the first and only FDA-cleared at-home PdG (progesterone metabolite) test in 2017. Since then, Proov's platform has expanded to measure all 4 reproductive hormones in urine. These tests are paired with pattern recognition and advanced analytics to truly understand how hormonal changes affect women's health and allow for personalized interventions to treat women quickly and effectively, even at home.

Daré Bioscience is a purpose-driven health biotech company focused solely on closing the gap between promising science and real solutions in women’s health. Our targeted therapeutics are based in advanced science, backed by rigorous research and validated by peer review. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we’re closing critical gaps in care using science that serves her needs.

Women in midlife have long been underserved by traditional healthcare—and most new solutions have not fully addressed the real barriers: access, clinical efficacy, and cost. In this session, Midi Health shares how it built a new model that combines clinical rigor, consumer engagement, and deep partnerships with health system incumbents to scale high-quality menopause care nationwide. The talk will explore the strategic decisions behind Midi’s growth, what worked (and what didn’t), and how a new operating model for digital health can drive sustainable impact.

Evvy is unlocking precision women’s healthcare through novel, overlooked female biomarkers—starting with the vaginal microbiome. Evvy is one of the fastest growing women’s health companies in the US—enabling us to deliver innovative, high-quality care while scaling novel R&D to unlock a new, data-driven future in women’s health. Evvy’s Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing.

Over the past several decades there has been a significant increase in the rates of high-risk pregnancies requiring greater clinical care. At the same time, we have a growing shortage of maternal-healthcare providers, creating barriers to care for women throughout the US. There is an urgent need to redesign care delivery to ensure the highest-risk patients get access to care to improve birth outcomes. Bloomlife is designing the future of maternal-care delivery through the most advanced combination of technology, data science, and clinical expertise.  

We conducted a retrospective, propensity score–matched cohort study using commercial claims data to evaluate the effectiveness of Visana Health, a comprehensive virtual women’s health care and navigation model (600 participants; 2,941 controls). Over six months, enrollment was associated with a $3,429 reduction in total allowed costs per member (P=0.02), driven by decreased facility, professional, and gynecologic spending, alongside reduced inpatient and emergency department utilization. Results support integrated virtual women’s care as an effective model for improving outcomes while lowering total cost of care.

Preterm birth drives infant morbidity, yet current tools rarely warn early enough. In this talk, Robert Bunn, founder of Ultrasound AI, shows how prenatal ultrasound becomes a predictive signal with AI to estimate delivery timing and flag preterm risk weeks earlier. The approach requires no new equipment or workflow, enabling low-cost deployment. Bunn outlines the concept, clinical validation plan, and partnerships needed to translate prediction into prevention.

Ananya Health is a medical device company building a platform to freeze and destroy abnormal tissue before it becomes cervical cancer. By removing the need for consumable cryogen, the platform delivers standard-of-care outcomes at a fraction of the cost of traditional cryoablation and enables providers at all levels of care to treat precancerous lesions. The Ananya Health team has five decades of medical device experience from concept to commercialization, and the company is backed by top investors, including YCombinator, NIH, EHA Impact Ventures, and BrightEdge Ventures, the investment arm of the American Cancer Society.

Women’s health has been ignored or narrowly defined as reproductive health. That framing is being challenged, and women are driving the change. Women’s health represents the most powerful platform for predictive, longitudinal, and integrated healthcare innovation. This talk reframes women’s health as infrastructure connecting market forces, emerging technology, and the healthcare economy. Attendees will gain perspective on where value is being created in healthcare, and why women are driving it.

Maternal health is at an inflection point. Birth rates among women over 40 have risen nearly 200% in the past three decades, while Millennials and Gen Z enter pregnancy with historically high anxiety and stress, Dionysus Healthcare is building AI-driven epigenetic platforms to predict maternal mental health risk before symptoms appear and quantify pregnancy related biologic aging and resilience, positioning pregnancy as the future gateway to longevity medicine.

Women with chronic, under-researched diseases such as endometriosis face a diagnostic and therapeutic landscape that is delayed, invasive, and often ineffective. PrecisionLife is transforming this paradigm. Our proprietary combinatorial analytics and AI platform has uncovered previously invisible patterns of genetic risk and disease mechanisms across large-scale population data. We’ve used these insights to develop a new class of diagnostic tools called mechanostics – non-invasive, highly predictive tests that identify underlying drivers.

BioSens8 is engineering a live data stream of our health state. Sensing a multitude of biomarkers continuously and in real-time with novel wearables will open the door to health ownership, personalized medicine, and proactive, data-driven decisions. One of BioSens8's first products is a continuous hormone monitor for female sex hormones designed to empower women with unprecedented insight and control over their health.